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Abstract
Purpose of Review Fatigue in primary biliary cholangitis patients is a frequently encountered and often debilitating symptom.
With no currently approved drug therapies available to target fatigue as a symptom, managing these patients can be very
challenging in a day-to-day clinical practise. We have critically appraised currently available evidence on various pharmacolog-
ical agents trialled in the management of fatigue in PBC.
Recent Findings Most recently, a randomised controlled trial from Newcastle group using Rituximab in high fatigue patients has
shown equivocal results for the improvement of fatigue, with a significant placebo effect. The data suggest that the general use of
Rituximab for the treatment of fatigue in PBC is not supported; however, there was evidence suggesting improvement of muscle
metabolic dysfunction linked to peripheral fatigue, and it may be that the agent has value in a carefully selected subgroup of
patients with, in particular, peripheral fatigue. Further work is needed in this area. In addition, there are several non-
pharmacological interventions which are available and can be considered in management of fatigue in PBC patients.
Summary A combination of non-pharmacological and currently non-licenced pharmacological therapies may be required in
managing fatigue in PBC patients.
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Introduction
Primary biliary cholangitis (PBC) is a chronic cholestatic liver
disease with a significant autoimmune component. It is
characterised by progressive immune-mediated small and in-
termediate intrahepatic duct damage leading eventually to cir-
rhosis and associated complications. PBC has a female pre-
ponderance with a female/male ratio of 9:1. Diagnostic crite-
rions set out in the EASL 2017 guidelines suggest that, in
adult patients with cholestasis and no likelihood of systemic
disease, a diagnosis of PBC can be made based on elevated
ALP and the presence of anti-mitochondrial antibody (AMA)
at a titre ≥ 1:40 [1].
Clinical presentation of PBC ranges from asymptomatic
patients who have been found incidentally to have abnor-
mal liver chemistry to patients presenting with complica-
tions of cirrhosis [2, 3]. It is now increasingly recognised
that there is an additional clinical problem related to sys-
temic symptoms of PBC, namely fatigue, pruritus, cogni-
tive symptoms leading to social isolation and emotional
dysfunction [4]. A patient-derived and fully validated as-
sessment tool, the PBC-40, with domains covering local-
ised symptoms, itch, fatigue, social, cognition and emo-
tional dysfunction, is widely used in clinical practise and
clinical trials as a patient-derived measure of quality of life
[5]. Importantly, currently available first-line therapy
Ursodeoxycholic acid (UDCA) and second-line therapies
Obeticholic acid (OCA) are both ineffective in improving
PBC-related symptoms [6, 7]. In this article, we focus on
understanding the pathophysiology, impact on quality of
life and available evidence on management of fatigue in
PBC.
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Impact of Fatigue in PBC
Fatigue is the most commonly reported symptom in PBC pa-
tients with 40–80% of patients encountering the symptom
during the course of their illness. In addition to having debil-
itating physical effect on patients’ ability to perform usual
day-to-day activities, fatigue also significantly impacts on
mental health, social life, family life, sexual life and job per-
formance [4, 8, 9]. This is exemplified by an early Canadian
study by Cauch-Dudek and colleagues which reported fatigue
in 81% of PBC patients, with 7% reporting fatigue interfering
with their physical activity, 57% family life and 30% job per-
formance [10]. Poor sleep quality and depression were fre-
quently reported to be related to fatigue. Verbally reported
fatigue of longer than 6-month duration was reported in 68%
patients with equal rates in UDCA-treated and -untreated pa-
tients. Furthermore, no correlation was seen with patient age,
duration of disease, level of daily physical activity, bilirubin
levels or Mayo Risk Score. Fatigued patients had more diffi-
culty with global sleep quality as measured by Pittsburgh
Sleep Quality Index, reporting greater impairment in subjec-
tive sleep quality, habitual sleep efficiency, sleep disturbances
and daytime dysfunction. Fatigued patients reported higher
rates of depression symptoms (71%) compared to 18% in
non-fatigued patients [10]. Similar findings have been report-
ed in other studies [11, 12] including the nationwide UK-PBC
study, which added the observation that the impact of fatigue
on quality of life is greatest in younger patients [13•].
Pathogenesis of Fatigue in PBC
The pathophysiology of fatigue is poorly understood [14••].
PBC patients exhibit both peripheral and central components
to their fatigue (Table 1); the latter is characterised by neuro-
physiological abnormalities and is shown to be related to cog-
nitive symptoms, sleep disturbance and depression [10].
A complex interaction exists between depression, sleep dis-
turbance and fatigue in these patients and correlates with the
fatigue severity. In the UK-PBC studies of 2353 patients, the
investigators used the PBC-40 measure, the Epworth
Sleepiness Scale [ESS; a measure of daytime somnolence
(score range of 0–24) and an ESS of 10 or more indicates
clinically significant daytime somnolence], the Orthostatic
Grading Scale [OGS; a measure of vasomotor autonomic dys-
function (score range 0–20 and a score of ≥ 4 indicates signif-
icant vasomotor autonomic dysfunction)] and the Hospital
Anxiety & Depression Scale (HADS; a measure of depression
and anxiety) [15, 16]. Significant numbers of PBC patients
reported increased daytime somnolence contributing, in part,
to their fatigue. A significant correlation was seen between
fatigue severity and HADS-D score (p < 0.0001). In addition,
autonomic dysfunction showed significant correlation with
fatigue, cognitive impairment and sleep disturbance.
The role of autonomic dysfunction in fatigue development
has been explored in detail. In one study, autonomic dysfunc-
tion was assessed using the Composite Autonomic Symptom
Scale (COMPASS) and fatigue was assessed using the Fatigue
Impact Scale (FIS) in two groups. Phase 1 (derivation phase),
40 chronic fatigue syndrome (CFS) patients and 40 age- and
sex-matched controls; phase 2 (validation phase), 30 CFS pa-
tients, 37 normal controls and 60 patients with primary biliary
cirrhosis. Symptoms of autonomic dysfunction were strongly
and reproducibly associated with the presence of fatigue and
correlated with severity of fatigue. Total COMPASS score >
32.5 was identified to have a positive predictive value of 0.96
(95%CI 0.86–0.99) and a negative predictive value of 0.84
(0.70–0.93) for the diagnosis of CFS and PBC patients and
can be used to identify patients for targeted intervention stud-
ies [29]. The combination of depression with sleep distur-
bance and autonomic symptoms was seen more in patients
with severe fatigue. In a related study, around 35% patient
reported impaired perceived quality of life (QoL) (compared
from 6% in healthy controls, p < 0.0001) [30].
There are also emerging data suggesting the presence of
organic changes in the brains of PBC patients which may be
associated with fatigue and linked cognitive symptoms [31,
32]. These fall into two groups, those demonstrating imaging
Table 1 Pathogenesis of fatigue in PBC
Central causes of fatigue:
Depression
Sleep disturbance
Autonomic dysfunction
Organic changes in the brains (based on MRI studies)
Peripheral causes of fatigue:
Excessive deviation from aerobic to anaerobic metabolism and
resulting lactate accumulation.
Abnormal serum amino acid levels:
Decreased levels of valine, isoleucine, leucine and tryptophan.
Increased levels of tyrosine and phenylalanine
Autoimmune
Table 2 Drugs/therapies
trialled for management
of fatigue in PBC
1. Rituximab [17••]
2. Modafinil [18, 19]
3. Fluoxetine [20]
4. Antioxidants [21]
5. Ondansetron [22]
6. Methotrexate [23, 24]
7. Corticosteroids [25]
8. Fluvoxamine [26]
9. Plasmapheresis [27, 28]
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changes typically with advanced MR methodologies and
those demonstrating neurophysiological and function abnor-
mality [33, 34, 35•]. These changes suggest a fluid organic
process which may be amenable to therapeutic intervention.
Importantly, however, imaging change can be seen in the first
few months following disease presentation suggesting that
injury may start early in the disease process [36•]. It may be
that effective treatment of the processes linked to fatigue re-
quires early intervention.
The peripheral component of fatigue is described by PBC
patients as the inability to sustain physical activity, loss of
energy or feeling of “batteries being run down”. Using a hand
grip strength assessment protocol, it has been demonstrated
that fatigued PBC patients show significantly accelerated de-
cline in muscle function on repeated activity, with the rate of
decline in grip strength being strongly correlated to severity of
fatigue reported [37]. Intramuscular acidosis is a factor leading
to muscle fatigue during prolonged and intense muscle activ-
ity; leading to reduction in contractile force and shortening
velocity; and a prolongation of recovery time [38, 39].
Using cardio pulmonary exercise testing (CPET) in PBC
patients undergoing transplant assessment, a baseline lower-
ing in anaerobic threshold has been demonstrated compared
with controls [40]. Over 95% of the PBC patients exhibit high
titres of anti-PDH (pyruvate dehydrogenase) antibodies, di-
rected against E2 and E3BP components of PDH, a key
enzyme-regulating anaerobic metabolism. The level of bioen-
ergetic mitochondrial abnormalities is directly related to anti-
PDH levels [41, 42]. These findings suggest a possible exces-
sive deviation from aerobic to anaerobic metabolism in fa-
tigued PBC patients leading to excessive lactic acid
accumulation.
Abnormal serum amino acid levels have also been im-
plicated in the development of fatigue in PBC as observed
in other chronic liver diseases. A study by Brog et al. dem-
onstrated that PBC patients had significantly decreased
levels of valine, isoleucine, and leucine. Tyrosine and phe-
nylalanine were increased (p < 0.0002) and tryptophan de-
creased (p < 0.0001) in PBC. Furthermore, in fatigued PBC
patients a significant inverse relation between tyrosine con-
centrations and fatigue and quality of life was found.
Patients without fatigue and with good quality of life had
increased tyrosine concentrations compared to fatigued pa-
tients [43].
In addition to directly disease mechanism-associated
processes, it should be borne in mind that PBC is associ-
ated with other autoimmune conditions which are them-
selves associated with treatable fatigue [44]. There is high
prevalence (up to 22%) of autoimmune hypothyroidism in
PBC patients with a 20% prevalence of anti-thyroglobulin
antibodies. Fatigue, lethargy and anorexia are among the
array of symptoms that are common to hypothyroidism and
PBC. Hence, in PBC patients who have concurrent
hypothyroidism, the latter contributes at least partially to
fatigue and is a very much treatable cause. It has been
demonstrated that these symptoms improve with thyroxine
supplementation [45].
Management of Fatigue in PBC
Currently, there is no recommended, licenced therapy available
to treat fatigue in PBC patients, though various agents have
been trialled (Table 2). Our approach to management is there-
fore supportive, aimed at treating reversible contributors to fa-
tigue and co-morbid diseases which may exacerbating it; the
“so called treatable causes contributing to the fatigue”. These
include, for example, hypothyroidism, itch (causing sleep dis-
turbance and resultant day time fatigue and somnolence) and
depression (Table 3). In addition, various non-pharmacological
measures can help provide patients with coping and supportive
strategies (Table 4). These include energy pacing and daytime
planning (fatigue is typically worse later in the day meaning
that it is helpful for patients to plan important activities for the
morning. This structured approach, although lacking the head-
line impact of an effective drug can, nonetheless, lead to signif-
icant quality of life improvement [14••, 46].
Drug Therapy and Other Interventions
for Fatigue in PBC Patients
There are currently no licenced drug therapies for the treat-
ment of fatigue in PBC. Furthermore, there is no evidence to
suggest that either of the currently licenced treatments (UDCA
and OCA) for progression prevention is effective in reducing
fatigue. A number of agents have been evaluated in clinical
trials for the treatment of fatigue in PBC (Table 2).
Table 3 Other pharmacological interventions (adapted from Best
Practice & Research Clinical Gastroenterology, Vol 34, Amardeep
Khanna, et al., Symptoms of PBC–Pathophysiology and management,
41–47, June–August 2018, with permission from Elsevier)
1. Treat depression
2. Treat Sicca syndrome
3. Treat vitamin D deficiency
4. Treat restless leg syndrome
5. Manage autonomic dysfunction:
Stop inappropriate anti-hypertensives
Keep well hydrated
TED stockings
6. Rule out obstructive sleep apnoea
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Rituximab Rituximab, an anti-CD20 monoclonal antibody
that selectively depletes B cells, is an effective immunothera-
py in autoimmune disease with a strong autoantibody re-
sponse. B cell and T cell responses to the E2 subunit of the
inner mitochondrial membrane enzyme pyruvate dehydroge-
nase complex have been implicated in the pathogenesis of
PBC. Rituximab has shown to significantly decrease serum
levels of total IgG, IgM and IgA as well as AMA [47, 48]. In a
single-centre double-blinded placebo-controlled trial, 57 par-
ticipants (aged ≥ 18 years with PBC and moderate or
severe fatigue (PBC-40 fatigue domain score of > 33))
were randomised to receive two doses of either rituximab
(1000 mg) or saline (placebo). The primary outcome measure
was the difference between intervention and control groups at
12 weeks in the fatigue domain score of the PBC-40.
Improvement in fatigue was seen in the Rituximab-treated
group (n = 28, falling from 41.2 ± 5.5 to 36.2 ± 8.4 at
3 months). A similar magnitude fall was, however, also seen
in the placebo group (43.0 ± 5.9 to 38.1 ± 8.7). Following ad-
justment for baseline characteristics, fatigue severity was low-
er in the Rituximab-treated group; however, this was not sta-
tistically significant. Rituximab therapy was safe with no se-
rious adverse events [17••].
Modafinil The CNS stimulant drug modafinil has an
established role in the treatment of excessive daytime somno-
lence in non-liver disease states. An open label study explored
the responses of modafinil therapy in 21 PBC patients suffer-
ing from significant daytime somnolence as assessed by
Epworth Sleepiness Scale [18]. In keeping with previous ob-
servations, this group had very prominent fatigue when
assessed using the PBC-40. Significant improvement was
seen in Epworth Sleepiness Scale scores (15 ± 3 vs. 8 ± 6,
P < 0.0005), was seen with modafinil therapy, and this was
accompanied in improvement in fatigue severity [PBC-40
fatigue domain score (46 ± 6 vs. 34 ± 12, P < 0.0001)] [18].
A further study, exploring the utility of modafinil in patients
not characterised by significant daytime somnolence, showed,
unsurprisingly, given the mode of action of the drug, no ben-
efit for fatigue [19]. Taken together, the data suggest that
modafinil should not be used as a treatment for fatigue per
se but may have value in the subgroup of patients where fa-
tigue is contributed to by significant daytime somnolence.
FluoxetineA double-blind, placebo-controlled study analysed
the safety and efficacy of fluoxetine for the treatment of fa-
tigue in PBC. Patients were randomised to two groups to
receive 20 mg fluoxetine once daily, or matched placebo for
8 weeks. The primary study endpoint was a > or = 50% re-
duction in overall Fisk Fatigue Impact Scale FFIS score at the
end of treatment (a very high bar for a fatigue trial end-point).
Health-related quality of life (HRQL) was assessed as a sec-
ondary endpoint. No statistically significant change in median
FFIS score and HRQL was observed in the fluoxetine group
after 8 weeks of therapy [20].
Antioxidants A trial using two compound antioxidant prepa-
rations—Bio-Antox (containing the antioxidants selenium,
methionine, beta-carotene, vitamin C and vitamin E and
Bio-Quinone Q10 (containing the antioxidants coenzyme
Q10 and alpha-tocopherol)—reported improvement in fatigue
in 9 of 13 patients; at least in one domain of Fisk Fatigue Score
(r = 0.44, P < 0.05), even more so when taken together (69%
compared from 56% when bio-Antox taken alone) [49].
However, a placebo-controlled trial of oral antioxidant supple-
mentation failed to confirm benefit [21].
Ondansetron Ondansetron is a selective 5-HT3 receptor an-
tagonist with an effect on central serotonergic neurotrans-
mission alterations which were believed to be implicated in
the pathogenesis of fatigue in PBC. A multi-centre,
randomised, double-blind, placebo-controlled, crossover tri-
al evaluated the efficacy of ondansetron in fatigued PBC
patients [22]. Sixty patients with clinically stable PBC, a
Fatigue Severity Score > 4, and no other identifiable cause
for fatigue were randomised to receive ondansetron (4 mg)
or placebo orally 3 times daily for 4 weeks. Subjects then
crossed over, after a 1-week washout period, for a further
4 weeks of ondansetron or placebo. In the placebo phase
period 1, there was no significant fatigue reduction (as mea-
sured by a Fatigue Severity Score (FSS) and Fatigue
Impact Scale (FIS) with ondansetron compared to placebo.
During period 2, FSS and FIS decreased significantly in
ondansetron group (p = 0.001). However, there is a widely
held view that these results were influenced by drug side
effects such as constipation unblinding subjects and later
clinical experience would support the view that ondansetron
has no role in treating PBC-related fatigue.
Table 4 Non-
pharmacological
interventions (adapted
from Best Practice &
Research Clinical
Gastroenterology, Vol
34, Amardeep Khanna,
et al., Symptoms of
PBC–Pathophysiology
and management, 41–47,
June–August 2018, with
permission from
Elsevier)
1. Patient engagement and encouraging
patients to take ownership of their
problem
2. Energy management-plan the daily
activities and tailor them according to
the hours and activities’ where most
fatigue is experienced.
3. Graded exercise
4. Physiotherapy
5. Occupational therapist
6. Psychologist
7. Smoking cessation advice
8. Engaging with employers to develop
supportive work patterns
9. Engagement in patient awareness
groups
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Methotrexate A pilot study of five patients with stage I-III
PBC treated with weekly methotrexate (MTX) for 15 months
reported improvement in fatigue in three (60%) patients [23].
Another study using a combination of UDCA and MTX re-
ported conflicting results with no improvement in symptoms
and one patient withdrawing from the study due to extreme
fatigue [24].
Corticosteroids A study combining UDCAwith prednisolone
showed improvement in symptoms in conjunction with bio-
chemical improvement with fatigue disappeared in four of six
symptomatic patients [25]. There is no high-quality evidence
to determine whether there is a clinically significant effect.
Fluvoxamine In a randomised placebo-controlled trial of the
antidepressant fluvoxamine, 17 patients received fluvoxamine
and 16 received placebo for a period of 6 weeks. Fatigue and
quality of life were measured using a visual analogue scale,
the Fisk Fatigue Severity Scale, the Multidimensional Fatigue
Inventory and the SF-36 did not show any statistically signif-
icant beneficial effect of fluvoxamine [26].
Plasmapheresis A pilot study of six patients with stage III-IV
PBC with symptoms refractory to pharmacological therapy
and undergoing plasma exchange therapy for mean period of
40 weeks demonstrated improvement in fatigue in four of the
six (67%) patients [50]. A similar study of five patients who
underwent a mean of 63 plasmapheresis procedures over a
mean of 112 weeks also showedmoderate reduction in fatigue
[27]. The significance of this effect is not clear and the ap-
proach has not entered clinical use for this indication.
Role of Liver Transplant in Treating Fatigue
Current evidence does not support liver transplantation for
fatigue as a main indication in PBC. An earlier study reported
a significant improvement in quality of life related to the
symptoms of cholestatic liver diseases (PBC and PSC) when
compared pre- and post-liver transplant (p < 0.01). Even
though fatigue was still among the top rated most distressing
symptoms even post-transplant, however, there was reduction
in intensity (reported as quite a bit distressed pre-transplant to
a little bit distressed post-transplant) [51]. Another study re-
ported significantly higher levels of fatigue (measured by me-
dian FIS) in PBC patients (n = 136) compared to community
controls (P < 0.0001) and chronic liver disease controls
(P < 0.05) and did not show any significant changes in fatigue
score in 11 patients undergoing liver transplantation compared
to those in non-transplanted patients with advanced disease
[4]. Therefore, current evidence is insufficient to support the
routine use of liver transplantation in the management of fa-
tigued PBC patients [52].
Conclusion
Fatigue in PBC patients has a significant impact on their phys-
ical, social, and psychological well-being. With no current
licenced therapy available to treat fatigue, there is a huge
unmet need which needs addressing. The current mainstay
of management is largely supportive. Engaging with patients
and exploring their expectations; clear communication about
the available evidence and non-pharmacological interventions
are cornerstones in managing these patients. Modafinil though
not evidence based may be considered as non-licenced thera-
py in subgroup of patients with day time somnolence after
obstructive sleep apnoea and other contraindications have
been ruled out. Further research in developing therapies to
deal with fatigue is required.
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